Dr. Reddy's Laboratories has entered into agreements with Schering and Sepracor which will allow itself to manufacture and market generic versions of the CLARINEX-D 12 Hour and CLARINEX-D* -24 Hour products, with six months marketing exclusivity, and the CLARINEX* REDITABS* product, with six months marketing co-exclusivity, starting in 2012, Dr, Reddy's will also market a generic version of the CLARINEX* 5 milligram tablet six months after the launch of the first generic version of that product.
The agreements resolve all pending patent infringement actions filed by Schering and Sepracor against Dr. Reddy's in the U.S. District Court for the District of Mew Jersey. The agreements provide for potential modification of select terms based on certain events and developments. Total U.S. sales for all formulations of CLARINEX® products were $362 million in 2007. CLARINEX is antihistamine and decongestant combination treatment to provide relief of nasal and non-nasal allergy symptoms.